AUROPHARMA - IntraDay Trade Analysis with Live Signals
Back to ListHere’s the intraday trading report for AUROPHARMA based on the given parameters
IntraDay Trade Rating: 3.8
| Stock Code | AUROPHARMA | Market Cap | 83,868 Cr. | Current Price | 1,444 ₹ | High / Low | 1,550 ₹ |
| Stock P/E | 34.5 | Book Value | 391 ₹ | Dividend Yield | 0.28 % | ROCE | 13.0 % |
| ROE | 11.2 % | Face Value | 1.00 ₹ | DMA 50 | 1,418 ₹ | DMA 200 | 1,287 ₹ |
| Chg in FII Hold | 1.29 % | Chg in DII Hold | -1.84 % | PAT Qtr | 692 Cr. | PAT Prev Qtr | 595 Cr. |
| RSI | 50.2 | MACD | -3.15 | Volume | 9,58,028 | Avg Vol 1Wk | 14,27,987 |
| Low price | 1,016 ₹ | High price | 1,550 ₹ | PEG Ratio | 1.33 | Debt to equity | 0.19 |
| 52w Index | 80.1 % | Qtr Profit Var | 69.6 % | EPS | 41.6 ₹ | Industry PE | 32.1 |
📊 Analysis: AUROPHARMA is trading above its 50 DMA (₹1,418) and 200 DMA (₹1,287), showing medium-term strength. RSI at 50.2 indicates neutral momentum, while MACD at -3.15 reflects mild bearish divergence. Intraday volume (9,58,028) is below the weekly average (14,27,987), suggesting weaker participation today. Fundamentals remain solid with EPS of ₹41.6 and PEG ratio of 1.33, though valuations are slightly stretched compared to industry PE (32.1).
💹 Optimal Buy Price: ₹1,435 – ₹1,450 (near DMA support)
🎯 Profit Exit Levels: ₹1,480 – ₹1,500 (resistance zone)
🛑 Stop-Loss: ₹1,420 (below DMA 50 support)
⏳ Exit Strategy if Holding: Exit intraday if RSI dips below 48 with rising sell volume or if price breaks under ₹1,420 with strong bearish candles. On the upside, partial profit booking is advised near ₹1,480–₹1,500 if momentum stalls.
✅ Positive
- PAT surged to ₹692 Cr. from ₹595 Cr. (+69.6%).
- EPS at ₹41.6 supports earnings visibility.
- PEG ratio at 1.33 indicates reasonable valuation relative to growth.
- FII holding increased (+1.29%), reflecting foreign investor confidence.
⚠️ Limitation
- Intraday volume weaker than weekly average, limiting momentum strength.
- P/E (34.5) slightly higher than industry PE (32.1).
- ROCE (13.0%) and ROE (11.2%) are moderate compared to sector leaders.
📉 Company Negative News
- DII holding decreased (-1.84%), showing reduced domestic institutional support.
- Stock trading near resistance zone (₹1,550), limiting immediate upside.
📈 Company Positive News
- Quarterly PAT growth of 69.6% indicates strong earnings momentum.
- FII inflows (+1.29%) strengthen investor sentiment.
- Dividend yield (0.28%) provides shareholder value.
🏭 Industry
- Pharma sector trading at industry PE of 32.1, slightly lower than AUROPHARMA’s valuation.
- Sector rotation favors pharma stocks, supporting medium-term demand.
🔎 Conclusion
AUROPHARMA is a solid intraday candidate today. Entry near ₹1,435–₹1,450 offers upside potential toward ₹1,480–₹1,500. However, weaker intraday volume and mild bearish MACD require disciplined stop-loss management. Suitable for momentum-driven trades with cautious profit booking.
Would you like me to extend this into a peer benchmarking overlay comparing AUROPHARMA with Sun Pharma, Dr. Reddy’s, and Cipla for sharper sector clarity?